Quince Therapeutics Statistics
Total Valuation
QNCX has a market cap or net worth of $35.87 million. The enterprise value is -$17.96 million.
| Market Cap | 35.87M |
| Enterprise Value | -17.96M |
Important Dates
The last earnings date was Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
QNCX has 43.22 million shares outstanding. The number of shares has increased by 19.96% in one year.
| Shares Outstanding | 43.22M |
| Shares Change (YoY) | +19.96% |
| Shares Change (QoQ) | +4.58% |
| Owned by Insiders (%) | 13.07% |
| Owned by Institutions (%) | 28.57% |
| Float | 29.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.48 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.16, with a Debt / Equity ratio of 0.19.
| Current Ratio | 7.16 |
| Quick Ratio | n/a |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -36.80% and return on invested capital (ROIC) is -32.54%.
| Return on Equity (ROE) | -36.80% |
| Return on Assets (ROA) | -24.20% |
| Return on Capital (ROIC) | -32.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$946,250 |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QNCX has paid $82,000 in taxes.
| Income Tax | 82,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.67% in the last 52 weeks. The beta is 1.23, so QNCX's price volatility has been higher than the market average.
| Beta (1Y) | 1.23 |
| 52-Week Price Change | -44.67% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 33.63 |
| Average Volume (30 Days) | 86,007 |
Short Selling Information
The latest short interest is 1.99 million, so 4.60% of the outstanding shares have been sold short.
| Short Interest | 1.99M |
| Short Previous Month | 1.97M |
| Short % of Shares Out | 4.60% |
| Short % of Float | 6.79% |
| Short Ratio (days to cover) | 20.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.69M |
| Pretax Income | -30.20M |
| Net Income | -30.28M |
| EBITDA | -29.85M |
| EBIT | -30.20M |
| Earnings Per Share (EPS) | -$0.76 |
Balance Sheet
The company has $67.82 million in cash and $14.00 million in debt, giving a net cash position of $53.83 million or $1.25 per share.
| Cash & Cash Equivalents | 67.82M |
| Total Debt | 14.00M |
| Net Cash | 53.83M |
| Net Cash Per Share | $1.25 |
| Equity / Book Value | 74.18M |
| Book Value Per Share | 1.72 |
| Working Capital | 60.60M |
Cash Flow
In the last 12 months, operating cash flow was -$23.08 million and capital expenditures -$63,000, giving a free cash flow of -$23.14 million.
| Operating Cash Flow | -23.08M |
| Capital Expenditures | -63,000 |
| Free Cash Flow | -23.14M |
| FCF Per Share | -$0.54 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
QNCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.96% |
| Shareholder Yield | -19.96% |
| Earnings Yield | -84.42% |
| FCF Yield | -64.51% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |